Microbio closes latest investment round after surpassing $3.5m target

Queensland biotechnology scale-up Microbio has closed its latest investment round after surpassing its $3.5 million target. This investment will facilitate Microbio expanding regulatory approval into international markets, having already received clearance for distribution and use in Europe and the UK, with approval in India and South America expected by the end of 2022, and TGA… Continue reading Microbio closes latest investment round after surpassing $3.5m target

Microbio’s bloodstream infection test cleared for sale in Europe

Australian biotech scaleup, Microbio is set to break into the European market with its flagship bloodstream infection (BSI) test. Following extensive clinical evaluation trials, the company has been granted a CE Mark, which has opened the door for distribution and use in Europe. Read more in the media release: 220614_Australian_bloodstream_infection_test_cleared_for_sale_in_Europe

Microbio presents posters at ECCMID 2022

Microbio presented two posters at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which took place in Lisbon, Portugal from April 23-26 2022. The conference provided CEO Paul Carboon and European Regional Manager Dr Raffaella Giardino the opportunity to present Microbio’s bloodstream infection test to delegates interested in improving the management of… Continue reading Microbio presents posters at ECCMID 2022

Introducing Microbio’s new consultant – Dr Raffaella Giardino

Microbio’s new consultant Dr Raffaella Giardino has extensive experience in highly regulated markets such as in vitro diagnostics (IVD), medical devices, and pharmaceuticals, as well as new market development, operations, finance, sales, and marketing. In her role as a remote consultant, Raffaella will support Microbio as it moves into Europe with the Blood Stream Infection… Continue reading Introducing Microbio’s new consultant – Dr Raffaella Giardino